This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
The recent report by Tourtellotte et al (Archives 1980; 37:723-726) describing their study of the use of an increased ratio of carbidopa to levodopa in the treatment of Parkinson's disease is rather difficult to interpret. The authors used an investigational design that allowed them to study three separate groups of patients with Parkinson's disease who had ceased receiving levodopa or carbidopa-levodopa (10:100) for at least one month. These groups of patients were treated with either levodopa, carbidopa-levodopa (10:100), or carbidopa-levodopa (20:100), and their degree of parkinsonian disability was evaluated. The response of the patients to these three different treatment regimens after a two-week period was used to conclude that increasing the amount of carbidopa in presently available drugs is a desirable treatment modality.Although the authors do state that their study "was conducted over a relatively short period," Parkinson's disease, in particular the therapy of Parkinson's disease
Weiner WJ, Nausieda PA. Carbidopa-Levodopa Ratio in Parkinson's Disease. Arch Neurol. 1981;38(8):534. doi:10.1001/archneur.1981.00510080096020
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.